Telotristat Etiprate for Carcinoid Syndrome Therapy – TELECAST

• Research type

  Research Study

• Full title

  A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome

• IRAS ID

  134283

• Contact name

  Martyn Caplin

• Contact email

  m.caplin@ucl.ac.uk

• Sponsor organisation

  Lexicon Pharmaceuticals, Inc.

• Eudract number

  2013-001543-31

• ISRCTN Number

  n/a

• REC name

  South Central - Hampshire B Research Ethics Committee

• REC reference

  13/SC/0559

• Date of REC Opinion

  2 Jan 2014

• REC opinion

  Further Information Favourable Opinion